Efficacy of sunitinib in advanced medullary thyroid carcinoma: Intermediate results of phase II THYSU

Oncologist

Volumn 15, Issue 2, 2010, Pages 212-213

  Ravaud, Alain ^a   De La Fouchardière, Christelle ^a   Asselineau, Julien ^a   Delord, Jean Pierre ^a   Cao, Christine D O ^a   Niccoli, Patricia ^a   Rodien, Patrice ^a   Klein, Marc ^a   Catargi, Bogdan ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCITONIN; SUNITINIB;

ADULT; ADVANCED CANCER; CALCITONIN BLOOD LEVEL; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KARNOFSKY PERFORMANCE STATUS; LETTER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; POPULATION; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; HUMANS; INDOLES; PYRROLES; THYROID NEOPLASMS;

EID: 77649112149     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0303     Document Type: Letter

References (3)

1. Bugalho MJ, Domingues R, Borges A. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib. The Oncologist 2009;14:1083-1087.
2. Ravaud A, De la Fouchardière C, Courbon F et al. Sunitinib in patients with refractory advanced thyroid cancer: The THYSU phase II trial [abstract 6058]. J Clin Oncol 2008;26:330s.
3. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961;13:346-353.